MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$4,160K
EPS
-$2.94
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-09-30
Research and development
2,558
2,587
2,361
General and administrative
1,592
1,600
2,687
Total operating expense
4,150
4,187
5,048
Loss from operations
-4,150
-4,187
-5,048
Interest expense-Nonrelated Party
29
33
31
Interest expense-Related Party
6
5
10
Change in fair value of other liabilities and derivatives-Nonrelated Party
1
-45
93
Change in fair value of other liabilities and derivatives-Related Party
-
-3
7
Other income (expense), net
31
73
18
Total other income (expense), net
-5
83
-123
Loss before income taxes
-4,155
-4,104
-5,171
Income tax provision
5
4
10
Net loss
-4,160
-4,108
-5,181
Net loss attributable to noncontrolling interest
-
-
-32
Net loss attributable to controlling interest
-4,160
-4,108
-5,149
Deemed dividend on warrants
-
-309
-5,673
Net loss attributable to common stockholders
-4,160
-4,417
-10,822
Basic EPS
-2.94
-0.43
-2.21
Diluted EPS
-2.94
-0.43
-2.21
Basic Average Shares
1,416,000
10,308,000
4,907
Diluted Average Shares
1,416,000
10,308,000
4,907
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$4,160K
Net loss
attributable to controlling...
-$4,160K
Net loss
-$4,160K
Loss before income
taxes
-$4,155K
Income tax provision
$5K
Loss from operations
-$4,150K
Total other income
(expense), net
-$5K
Other income
(expense), net
$31K
Total operating
expense
$4,150K
Interest
expense-Nonrelated Party
$29K
Interest
expense-Related Party
$6K
Change in fair value of
other liabilities and...
$1K
Research and development
$2,558K
General and
administrative
$1,592K
Buy us a coffee
Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc. (CLDI)